Q2 EPS Estimate for Daré Bioscience Increased by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Brookline Capital Management increased their Q2 2025 EPS estimates for Daré Bioscience in a research note issued on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now forecasts that the biotechnology company will post earnings per share of ($0.48) for the quarter, up from their prior estimate of ($0.62). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.57) EPS and FY2025 earnings at ($2.03) EPS.

Daré Bioscience (NASDAQ:DARE) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.60 million. During the same period last year, the business posted ($0.84) earnings per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a report on Tuesday, April 1st.

Daré Bioscience Stock Performance

DARE stock opened at $2.89 on Friday. The firm has a fifty day moving average price of $2.92 and a 200 day moving average price of $3.17. Daré Bioscience has a fifty-two week low of $2.67 and a fifty-two week high of $7.56. The firm has a market cap of $25.58 million, a PE ratio of -4.89 and a beta of 1.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Daré Bioscience by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after buying an additional 3,593 shares during the period. Renaissance Technologies LLC boosted its stake in Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after buying an additional 4,300 shares during the period. AMH Equity Ltd boosted its stake in Daré Bioscience by 9.5% during the first quarter. AMH Equity Ltd now owns 164,302 shares of the biotechnology company’s stock worth $475,000 after buying an additional 14,302 shares during the period. Finally, Jane Street Group LLC purchased a new position in Daré Bioscience during the fourth quarter worth $52,000. 6.70% of the stock is owned by hedge funds and other institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.